

- (51) International Patent Classification:
A61K 9/16 (2006.01) A61K 31/513 (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/US2024/014585

(22) International Filing Date:
06 February 2024 (06.02.2024)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
63/483,486 06 February 2023 (06.02.2023) US

(71) Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: ANDERSEN, Sune; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). DRIESEN, Regina; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). VANHOUTTE, Filip; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). VAN DROOGENBROECK, Annelien; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). VAN SNICK, Bernd; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). VAES, Elise; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: LODISE, Stephanie A. et al.; BAKER-HOSTETLER, 1735 Market Street, Suite 3300, Philadelphia, Pennsylvania 19103-7501 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(54) Title: MILVEXIAN PHARMACEUTICAL COMPOSITIONS




Fig. 1

(57) Abstract: Solid pharmaceutical compositions of a FXIa inhibitor for oral administration are provided.